FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to the use of a population of extracellular vesicles (EV) of plant origin in the therapeutic treatment of impaired angiogenesis. Use of a plant-derived population of extracellular vesicles (EVs) derived from a plant selected from the group consisting of orange, lemon, grapes, Anastatica hierochuntica (AH) and Selaginella lepidophylla (SL), wherein the extracellular vesicles (EVs) in the said population are confined to a lipid bilayer membrane and have a diameter ranging from 25 to 350 nm, and a protein content ranging from 1 to 55 ng/109 EV, in the therapeutic treatment of impaired angiogenesis.
EFFECT: above-described plant-derived vesicles used are effective for the therapeutic treatment of impaired angiogenesis.
8 cl, 19 dwg, 1 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EXTRACELLULAR VESICLES FOR INHALATION | 2019 |
|
RU2799315C2 |
| METHOD FOR TARGETED IMPACT ON EXOSOMES | 2018 |
|
RU2781640C2 |
| SUBSTANCES AND METHODS OF MODULATING TENDON HEALING | 2015 |
|
RU2699706C2 |
| EXTRACELLULAR VESICLES ORIGINATING FROM MESENCHYMAL STEM CELLS | 2019 |
|
RU2805066C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING microRNA-100 AND USE THEREOF IN MODULATING GROWTH OF BLOOD VESSELS AND ENDOTHELIUM INFLAMMATION | 2010 |
|
RU2586531C2 |
| VESICLES CONTAINING PTEN INHIBITOR AND THEIR USE | 2019 |
|
RU2800729C2 |
| COMPOSITIONS CONTAINING CELL VESICLES AND USE THEREOF | 2019 |
|
RU2824136C2 |
| DRUG FOR TREATMENT OF TISSUE FIBROSIS BASED ON COMPONENTS OF SECRETOME OF MESENCHYMAL STROMAL CELLS, METHOD FOR OBTAINING AND APPLYING REMEDY | 2020 |
|
RU2766707C1 |
| METHOD OF DETERMINING THE RISK OF MALIGNANT TRANSFORMATION OF PROSTATE CELLS | 2022 |
|
RU2806518C1 |
| METHOD FOR PRODUCING INDUCED REPROGRAMMED DERIVATIVE NEURONAL STEM CELLS FROM NON-NEURONAL CELLS BY USING HMGA2 | 2014 |
|
RU2646099C2 |
